Los Gatos, California-based Advanced NanoTherapies received the investment from a medical device company. It also announced the successful treatment of the first cohort of study participants in its drug-coated balloon trial. The first-in-human trial evaluates initial short-term safety data for the next-generation SirPlux Duo drug-coated balloon. It looks at the balloon in treating de novo coronary artery disease (CAD).
Get the full story at our sister site, Drug Delivery Business News.
Los Gatos, California-based Advanced NanoTherapies received the breakthrough nod for the use of the DCB in treating coronary artery disease in vessels less than 3.0mm. The regulatory win comes weeks after two previous breakthrough designations. SirPlux Duo already has breakthrough designation for coronary in-stent restenosis (ISR) and peripheral below-the-knee (BTK) lesions.
Get the full story at our sister site, Drug Delivery Business News.
Los Gatos, California-based Advanced NanoTherapies, which develops the SirPlux Duo drug-coated balloon (DCB) for treating de novo coronary artery disease (CAD) lesions, has now raised $12.5 million in total since September 2020.
Get the full story at our sister site, Drug Delivery Business News.